Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Beijing Tong Ren Tang Chinese Medicine Co ( (HK:3613) ) has shared an update.
Beijing Tong Ren Tang Chinese Medicine Co announced the retirement of Mr. Gu Hai Ou as the executive director, chairman of the board, and authorized representative, effective September 4, 2025, due to reaching retirement age. Mr. Yan Han has been appointed as the new chairman of the board, bringing extensive experience in international culture publicity and brand development, while Mr. Yue Zheng has been appointed as the new authorized representative. These leadership changes are expected to influence the company’s strategic direction and reinforce its position in the traditional Chinese medicine industry.
The most recent analyst rating on (HK:3613) stock is a Buy with a HK$10.50 price target. To see the full list of analyst forecasts on Beijing Tong Ren Tang Chinese Medicine Co stock, see the HK:3613 Stock Forecast page.
More about Beijing Tong Ren Tang Chinese Medicine Co
Beijing Tong Ren Tang Chinese Medicine Co is a company incorporated in Hong Kong, operating in the traditional Chinese medicine industry. It focuses on the development, manufacturing, and distribution of Chinese medicinal products, serving both domestic and international markets.
Average Trading Volume: 1,339,083
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.57B
Find detailed analytics on 3613 stock on TipRanks’ Stock Analysis page.